Who founded PharmEnable?

PharmEnable was founded by Hannah Sore.

Who are PharmEnable's investors?

PharmEnable's investors include Cambridge Angels group, Martlet Capital, MC Healthcare Ventures, O2h Ventures, Parkwalk Advisors, Wren Capital.

How much funding has PharmEnable raised?

PharmEnable has disclosed $7.5M raised across 1 round.

PharmEnable

11 employees on LinkedIn · 12 known investors

Find your way into PharmEnable

274 people in our graph share verified history with the PharmEnable team — schools, employers, funds. One of them is your warm intro.

Hannah Sealunlockedknows Hannah Sore · together at University of Cambridge (overlapped)

×11knows the team · via University of Cambridge

PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address. The company develops first- and best-in-class therapies and originated as a spin-out from the University of Cambridge.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Hannah Sore inFounderHannah Sore is a medicinal chemist and co-founder of PharmEnable, a drug discovery company using AI for small molecule development. She has prior experience in drug discovery roles at Millennium Pharmaceuticals and Astex Therapeutics, as well as research positions at Cambridge University and consulting work in healthcare.

Investors · 12

Cambridge Angels groupCambridge · $195K – $1.9M

Martlet CapitalCambridge · $317.5K

MC Healthcare VenturesCambridge

O2h Venturesreported · 2 sourcesCambridge

Parkwalk AdvisorsreportedLondon

Wren Capitalreported · 2 sourcesLondon

Also in the syndicate · 6

Arrowfield CapitalCambridge EnterpriseHeyford TrustMP HealthcareleadMP Healthcare Venture Management (MPH)leadUniversity of Cambridge Enterprise Fund VIII

Funding

SEC filings, press & company announcements

$7.5M disclosed across 1 round · 2023

$7.5MPre-Series AMay 2023 · 3 sources
MP Healthcare (lead), MP Healthcare Venture Management (MPH) (lead), Arrowfield Capital, Cambridge Enterprise, Heyford Trust, Martlet Capital, o2h Ventures, Parkwalk Advisors, University of Cambridge Enterprise Fund VIII, Wren Capital
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

PharmEnable Therapeutics Raises $7.5M in Series A Funding to Revolutionize Small Molecule Drug Discovery Using AIleadsontrees.com · Dec 2024

PharmEnable raises $7.5M in Pre-Series A funding round with a follow-on investment from o2h Ventures - o2h Ventureso2hventures.com · May 2023

PharmEnable Closes $7.5M Pre-Series Financingfinsmes.com · May 2023

PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseasesglobenewswire.com · May 2023

$7.5M Financing led by MP Healthcare - PharmEnable Therapeuticspharmenabletx.com · May 2023

£1.8 million for Drug Discovery Expansion - PharmEnable Therapeuticspharmenabletx.com · Jun 2020

Frequently asked questions

What does PharmEnable do?: PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address. The company develops first- and best-in-class therapies and originated as a spin-out from the University of Cambridge.
Who founded PharmEnable?: PharmEnable was founded by Hannah Sore.
Who are PharmEnable's investors?: PharmEnable's investors include Cambridge Angels group, Martlet Capital, MC Healthcare Ventures, O2h Ventures, Parkwalk Advisors, Wren Capital.
How much funding has PharmEnable raised?: PharmEnable has disclosed $7.5M raised across 1 round.